HemOnc Today

CURRENTLY VIEWING:

The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents
Commentary

Adjuvant and systemic therapy for rare tumors of the uterus and cervix

Erin K. Crane, MD; Jubilee Brown, MD; R. Wendel Naumann, MD

‘Cautiously reassuring’ picture emerges regarding sickle cell trait health risks

D. Alan Nelson, MPAS, PhD; Lianne M. Kurina, PhD

NYU Langone names liver tumor program director

Payment reform, ‘runaway growth’ of 340B top new Community Oncology Alliance president’s priorities

New ASH president: 'Extraordinary science' at genomic level must be brought to bedside

University of Chicago researcher receives NCI award

Dana-Farber surgical oncology chief to assume ASCO presidency in 2018

Cover Story

Active surveillance, physician–patient communication may redefine role of PSA testing

Editorial

Avoiding the obvious while running in diminishing circles

Derek Raghavan, MD, PhD

FDA News

FDA accepts biologics license application for proposed biosimilar to Neulasta

FDA grants priority review to inotuzumab ozogamicin for ALL

FDA approves Revlimid for myeloma maintenance after stem cell transplant

In the Journals Plus

Many nonelderly cancer survivors alter prescription drug use to save money

Sickle cell trait unrelated to fitness level, heart failure

SIOP scale best detects ototoxicity in children who receive cisplatin chemotherapy

Regular aspirin use may lower risk for pancreatic cancer

Scalp-cooling caps may reduce hair loss for women with breast cancer

Most adolescents, young adults not treated with pediatric ALL protocols

Considering bone marrow blasts from nonerythroid cells improves prognostication of MDS

Collection of patient-reported outcomes crucial for improving care

Cisplatin therapy effective for men with relapsed stage I seminoma

Avelumab shows promise in Merkel cell carcinoma

Changes in depression symptoms may influence lung cancer survival

Upfront surgery does not improve OS for patients with HPV–negative OPSCC

Meeting News

Reduced abiraterone acetate dose with low-fat meal maintains efficacy, saves costs

Use of antibiotics could reduce efficacy of immunotherapy

Point/Counter

Is genetic testing sophisticated enough to make PSA screening viable for mainstream use?

Supplement

Meeting Update: Clinicians discuss findings, practice implications from Gastrointestinal Cancers Symposium

Advertisement
Advertisement